Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Morgan Stanley Downgrades Intra-Cellular Therapies (ITCI) to Equalweight
January 13, 2025 9:54 AM ESTMorgan Stanley analyst Jeffrey Hung downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Overweight to Equalweight with a price target of $132.00 (from $102.00).
The analyst comments "JNJ announced this morning that it has entered into an agreement to acquire Intra-Cellular Therapies for $132/share. We downgrade... More
Intra-Cellular Therapies (ITCI) PT Raised to $140 at Mizuho
January 13, 2025 6:24 AM ESTMizuho analyst Graig Suvannavejh raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $140.00 (from $100.00) while maintaining a Outperform rating.
The analyst comments "We raise our PT on ITCI to $140 (vs. our prior $100), following a surprise (and, in our view, a far better than... More
Intra-Cellular Therapies (ITCI) PT Raised to $118 at BofA Securities
January 10, 2025 2:36 PM ESTBofA Securities analyst Jason Gerberry raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $118.00 (from $110.00) while maintaining a Buy rating.
The analyst comments "We raise our ITCI PO to $118 (from $100) after the company announced a favorable Caplyta patent settlement with Sandoz (1 of 7... More
